These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 28109775)

  • 1. Treatment of rats with the JAK-2 inhibitor fedratinib does not lead to experimental Wernicke's encephalopathy.
    Hazell AS; Afadlal S; Cheresh DA; Azar A
    Neurosci Lett; 2017 Mar; 642():163-167. PubMed ID: 28109775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Janus kinase 2 inhibitor fedratinib inhibits thiamine uptake: a putative mechanism for the onset of Wernicke's encephalopathy.
    Zhang Q; Zhang Y; Diamond S; Boer J; Harris JJ; Li Y; Rupar M; Behshad E; Gardiner C; Collier P; Liu P; Burn T; Wynn R; Hollis G; Yeleswaram S
    Drug Metab Dispos; 2014 Oct; 42(10):1656-62. PubMed ID: 25063672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Putamina involvement in Wernicke encephalopathy induced by Janus Kinase 2 inhibitor.
    Rodríguez-Pardo J; Puertas-Muñoz I; Martínez-Sánchez P; Díaz de Terán J; Pulido-Valdeolivas I; Fuentes B
    Clin Neuropharmacol; 2015; 38(3):117-8. PubMed ID: 25970282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
    Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Tiu RV; Zachee P; Jourdan E; Winton E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Lager J; Shun Z; Mesa RA
    Lancet Haematol; 2017 Jul; 4(7):e317-e324. PubMed ID: 28602585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis.
    Talpaz M; Kiladjian JJ
    Leukemia; 2021 Jan; 35(1):1-17. PubMed ID: 32647323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and future role of fedratinib in the treatment of myelofibrosis.
    Ragheb M; Harrison CN; McLornan DP
    Future Oncol; 2020 Feb; 16(6):175-186. PubMed ID: 31971457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Thiamine in patients with alcohol use disorder and Wernicke's encephalopathy].
    Brinkman DJ; Bekema JK; Kuijenhoven MA; Wijnia JW; Dekker MJ; van Agtmael MA
    Ned Tijdschr Geneeskd; 2017; 161():D931. PubMed ID: 28224875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis.
    Pardanani A; Tefferi A; Masszi T; Mishchenko E; Drummond M; Jourdan E; Vannucchi A; Jurgutis M; Ribrag V; Rambaldi A; Koh LP; Rose S; Zhang J; Harrison C
    Br J Haematol; 2021 Oct; 195(2):244-248. PubMed ID: 34331348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fedratinib: a pharmacotherapeutic option for JAK-inhibitor naïve and exposed patients with myelofibrosis.
    England JT; Gupta V
    Expert Opin Pharmacother; 2022 Oct; 23(15):1677-1686. PubMed ID: 36252265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Malnutrition-induced Wernicke's encephalopathy following a water-only fasting diet.
    Hutcheon DA
    Nutr Clin Pract; 2015 Feb; 30(1):92-9. PubMed ID: 25524882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thiamine deficiency and Wernicke's encephalopathy in AIDS.
    Butterworth RF; Gaudreau C; Vincelette J; Bourgault AM; Lamothe F; Nutini AM
    Metab Brain Dis; 1991 Dec; 6(4):207-12. PubMed ID: 1812394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fedratinib hydrochloride to treat intermediate-2 or high-risk primary or secondary myelofibrosis.
    Schiffer M; Kowalski A; Zhao J; Bewersdorf JP; Lewis RS; Zeidan AM
    Drugs Today (Barc); 2020 Dec; 56(12):755-768. PubMed ID: 33332482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.
    Pardanani A; Harrison C; Cortes JE; Cervantes F; Mesa RA; Milligan D; Masszi T; Mishchenko E; Jourdan E; Vannucchi AM; Drummond MW; Jurgutis M; Kuliczkowski K; Gheorghita E; Passamonti F; Neumann F; Patki A; Gao G; Tefferi A
    JAMA Oncol; 2015 Aug; 1(5):643-51. PubMed ID: 26181658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis.
    Pardanani A; Tefferi A; Jamieson C; Gabrail NY; Lebedinsky C; Gao G; Liu F; Xu C; Cao H; Talpaz M
    Blood Cancer J; 2015 Aug; 5(8):e335. PubMed ID: 26252788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective increase of neuronal cyclooxygenase-2 (COX-2) expression in vulnerable brain regions of rats with experimental Wernicke's encephalopathy: effect of nimesulide.
    Gu B; Desjardins P; Butterworth RF
    Metab Brain Dis; 2008 Jun; 23(2):175-87. PubMed ID: 18481165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thiamine deficiency results in downregulation of the GLAST glutamate transporter in cultured astrocytes.
    Hazell AS; Pannunzio P; Rama Rao KV; Pow DV; Rambaldi A
    Glia; 2003 Aug; 43(2):175-84. PubMed ID: 12838509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case of Wernicke's encephalopathy following fluorouracil-based chemotherapy.
    Cho IJ; Chang HJ; Lee KE; Won HS; Choi MY; Nam EM; Mun YC; Lee SN; Seong CM
    J Korean Med Sci; 2009 Aug; 24(4):747-50. PubMed ID: 19654964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of 2,4-Diaminopyrimidine-Containing Drugs Including Fedratinib and Trimethoprim with Thiamine Transporters.
    Giacomini MM; Hao J; Liang X; Chandrasekhar J; Twelves J; Whitney JA; Lepist EI; Ray AS
    Drug Metab Dispos; 2017 Jan; 45(1):76-85. PubMed ID: 27803021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thiamine deficiency results in metabolic acidosis and energy failure in cerebellar granule cells: an in vitro model for the study of cell death mechanisms in Wernicke's encephalopathy.
    Pannunzio P; Hazell AS; Pannunzio M; Rao KV; Butterworth RF
    J Neurosci Res; 2000 Oct; 62(2):286-92. PubMed ID: 11020221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective down-regulation of the astrocyte glutamate transporters GLT-1 and GLAST within the medial thalamus in experimental Wernicke's encephalopathy.
    Hazell AS; Rao KV; Danbolt NC; Pow DV; Butterworth RF
    J Neurochem; 2001 Aug; 78(3):560-8. PubMed ID: 11483659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.